703 related articles for article (PubMed ID: 33717414)
1. Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson's disease.
Nam D; Kim A; Han SJ; Lee SI; Park SH; Seol W; Son I; Ho DH
Anim Cells Syst (Seoul); 2021 Feb; 25(1):28-36. PubMed ID: 33717414
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
3. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients.
Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH
J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560
[TBL] [Abstract][Full Text] [Related]
4. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease.
Liu Z; Chan RB; Cai Z; Liu X; Wu Y; Yu Z; Feng T; Yang Y; Zhang J
J Neuroinflammation; 2022 Feb; 19(1):53. PubMed ID: 35193594
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
10. Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous
MacIsaac S; Quevedo Melo T; Zhang Y; Volta M; Farrer MJ; Milnerwood AJ
Brain Commun; 2020; 2(1):fcz052. PubMed ID: 32510053
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.
Aasly JO; Johansen KK; Brønstad G; Warø BJ; Majbour NK; Varghese S; Alzahmi F; Paleologou KE; Amer DA; Al-Hayani A; El-Agnaf OM
Front Aging Neurosci; 2014; 6():248. PubMed ID: 25309429
[TBL] [Abstract][Full Text] [Related]
12. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice.
Domenicale C; Mercatelli D; Albanese F; Novello S; Vincenzi F; Varani K; Morari M
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453631
[TBL] [Abstract][Full Text] [Related]
13. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
15. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric α-synuclein through NF-κB pathway.
He KJ; Zhang JB; Liu JY; Zhao FL; Yao XY; Tang YT; Zhang JR; Cheng XY; Hu LF; Wang F; Liu CF
iScience; 2023 Nov; 26(11):108130. PubMed ID: 37876795
[TBL] [Abstract][Full Text] [Related]
17. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
Gaig C; Martí MJ; Ezquerra M; Cardozo A; Rey MJ; Tolosa E
BMJ Case Rep; 2009; 2009():. PubMed ID: 21686713
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
20. Oral Mucosa Derived α-Synuclein as a Potential Diagnostic Biomarker for Parkinson's Disease.
Zheng Y; Yu Z; Zhao J; Cai H; Wang Z; Wang X; Feng T
Front Aging Neurosci; 2022; 14():867528. PubMed ID: 35418851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
